Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Generics [UK] Ltd t/a Mylan, Station Close, Potters Bar, Herts. EN6 1TL, United Kingdom
Oxcarbazepine Mylan 150 mg Film-coated Tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Buff, oblong, normal convex film-coated tablet debossed “OX|150” on one side and “G|G” on the other side. The tablet has a score line to facilitate breaking for ease of swallowing and not to divide into equal doses. |
Each film-coated tablet contains 150 mg oxcarbazepine.
Excipient with known effect: Each 150 mg tablet contains 1.23 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Oxcarbazepine |
The pharmacological activity of oxcarbazepine is primarily exerted through the metabolite (MHD). The mechanism of action of oxcarbazepine and MHD is thought to be mainly based on the blockade of voltage-sensitive sodium channels. |
| List of Excipients |
|---|
|
Tablet core: Crospovidone Tablet coating: Black iron oxide (E172) |
Clear PVC-PVdC/aluminium blisters.
Pack sizes: 10, 20, 30, 50, 60, 100, 200 film-coated tablets.
Polypropylene tablet containers with tamper evident polyethylene caps and optional polyethylene ullage filler.
Pack sizes: 100, 200, 500 film-coated tablets.
Not all pack sizes may be marketed.
Generics [UK] Ltd t/a Mylan, Station Close, Potters Bar, Herts. EN6 1TL, United Kingdom
PL 04569/0779
30/04/2011
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
